Headlines about Ocular Therapeutix (NASDAQ:OCUL) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocular Therapeutix earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.7078727572187 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Only the Technical Indicators on Ocular Therapeutix, Inc. (OCUL) – Wall Street Morning (wallstreetmorning.com)
- Ocular Therapeutix Inc (OCUL) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Hot Stock That Must Be … – Nasdaq Journal (nasdaqjournal.com)
- Active Stock Evaluation – Ocular Therapeutix, Inc. (NASDAQ: OCUL) – The Investor Guide (wallstreetnews24.com)
- Ocular Therapeutix, Inc. (OCUL) stock price traded 20.66% higher to its SMA-20 – The Stocks News (press release) (thestocksnews.com)
Shares of OCUL stock traded up $0.12 on Wednesday, hitting $6.73. 243,117 shares of the stock traded hands, compared to its average volume of 526,254. The firm has a market capitalization of $255.73, a P/E ratio of -3.00 and a beta of 1.51. Ocular Therapeutix has a 52 week low of $3.30 and a 52 week high of $11.79. The company has a current ratio of 3.23, a quick ratio of 3.22 and a debt-to-equity ratio of 0.48.
OCUL has been the subject of several recent research reports. BTIG Research reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Sunday, March 11th. ValuEngine upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Ocular Therapeutix in a report on Friday, March 9th. Cantor Fitzgerald reissued a “buy” rating and set a $22.00 price target on shares of Ocular Therapeutix in a report on Thursday, March 8th. Finally, Zacks Investment Research raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $11.92.
TRADEMARK VIOLATION WARNING: This report was first published by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://baseballnewssource.com/2018/03/21/ocular-therapeutix-ocul-receiving-somewhat-positive-press-coverage-report-shows/2029289.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.